- Home
- NUVL vs LFUS Comparison
NUVL vs LFUS Comparison
Compare NUVL & LFUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- LFUS
- Stock Information
- Founded
- NUVL 2017
- LFUS 1927
- Country
- NUVL United States
- LFUS United States
- Employees
- NUVL N/A
- LFUS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- LFUS Electrical Products
- Sector
- NUVL Health Care
- LFUS Energy
- Exchange
- NUVL Nasdaq
- LFUS Nasdaq
- Market Cap
- NUVL 5.8B
- LFUS 5.7B
- IPO Year
- NUVL 2021
- LFUS N/A
- Fundamental
- Price
- NUVL $78.64
- LFUS $260.40
- Analyst Decision
- NUVL Strong Buy
- LFUS Hold
- Analyst Count
- NUVL 11
- LFUS 3
- Target Price
- NUVL $120.91
- LFUS $234.50
- AVG Volume (30 Days)
- NUVL 390.3K
- LFUS 163.8K
- Earning Date
- NUVL 11-11-2025
- LFUS 10-28-2025
- Dividend Yield
- NUVL N/A
- LFUS 1.13%
- EPS Growth
- NUVL N/A
- LFUS N/A
- EPS
- NUVL N/A
- LFUS 4.29
- Revenue
- NUVL N/A
- LFUS $2,264,614,000.00
- Revenue This Year
- NUVL N/A
- LFUS $11.29
- Revenue Next Year
- NUVL N/A
- LFUS $7.51
- P/E Ratio
- NUVL N/A
- LFUS $61.80
- Revenue Growth
- NUVL N/A
- LFUS 1.34
- 52 Week Low
- NUVL $55.54
- LFUS $142.10
- 52 Week High
- NUVL $110.00
- LFUS $271.81
- Technical
- Relative Strength Index (RSI)
- NUVL 51.21
- LFUS 52.81
- Support Level
- NUVL $77.88
- LFUS $257.94
- Resistance Level
- NUVL $83.09
- LFUS $271.81
- Average True Range (ATR)
- NUVL 3.14
- LFUS 5.79
- MACD
- NUVL 0.14
- LFUS -0.69
- Stochastic Oscillator
- NUVL 48.79
- LFUS 43.23
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) into the transportation, industrial, telecommunications, and consumer electronics end markets. The firm is also increasing its power semiconductor business, where it predominantly serves industrial end markets and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.